How I monitor residual disease in chronic myeloid leukemia.
about
Towards Stratified Medicine in Plasma Cell MyelomaImpact of additional chromosomal aberrations and BCR-ABL kinase domain mutations on the response to nilotinib in Philadelphia chromosome-positive chronic myeloid leukemia.Interpreting molecular monitoring results and international standardization in chronic myeloid leukemia.Interpretation of cytogenetic and molecular results in patients treated for CML.Genomic quantitative real-time PCR proves residual disease positivity in more than 30% samples with negative mRNA-based qRT-PCR in Chronic Myeloid LeukemiaMajor molecular response in CML patients treated with tyrosine kinase inhibitors: the paradigm for monitoring targeted cancer therapyHow I treat childhood CML.Detection of t(9;22) b2a2 fusion transcript by flow cytometry.Clinical and prognostic significance of 3q26.2 and other chromosome 3 abnormalities in CML in the era of tyrosine kinase inhibitors.Chronic myeloid leukemia (CML) in children: classical and newer therapeutic approaches.BCR-ABL PCR testing in chronic myelogenous leukemia: molecular diagnosis for targeted cancer therapy and monitoring.BCR-ABL inhibitors: updates in the management of patients with chronic-phase chronic myeloid leukemia.Controversies in the assessment of minimal residual disease in multiple myeloma: clinical significance of minimal residual disease negativity using highly sensitive techniques.Molecular genetic evaluation of myeloproliferative neoplasms.Rationale and motivating factors for treatment-free remission in chronic myeloid leukemia.FuseFISH: robust detection of transcribed gene fusions in single cells.Blinatumomab for minimal residual disease in adults with B-precursor acute lymphoblastic leukemia.Measurement of BCR-ABL1 transcripts on the International Scale in the United States: current status and best practices.Characteristics of BCR-ABL kinase domain mutations in chronic myeloid leukemia from India: not just missense mutations but insertions and deletions are also associated with TKI resistance.
P2860
Q28074994-F74143A7-F547-4799-820A-0937451EB69CQ33518973-B62143F1-30A2-4EB2-9270-9DFB04F0A527Q33885583-69DA2ED5-FC30-4B2F-8E83-D15093BDCB51Q34765448-2F9F12EB-37C3-4DA3-8329-5247A832DC9FQ34781322-6DCDED88-ED48-44B0-88EC-879530009A7DQ35584176-EF250460-135D-490F-86D8-EDD14FCD40F6Q35802202-8C487031-BF13-4B0D-918F-47AD8E1F2E32Q36053716-736DE2F4-5951-430D-8520-28FC0918D614Q36219652-55338271-DCFD-4EAB-8DC0-87EA4ADE6DE9Q38018109-3A526B0A-487C-41D3-BE81-8C425978E511Q38142258-27D93B7E-D55E-4793-BF7D-59D7F5740D1FQ38154292-637407D0-BDA7-454F-B152-35DB12862E09Q38249930-E7FE2377-930B-4392-B2D3-8660E9D1D95AQ38481945-4E37C205-E4D3-4829-AF04-53BB9E326082Q38937497-A8A96936-5409-4992-A641-2477C9C5BC1DQ39038984-7B799BF1-6AA8-4E87-9E40-3A02919018DFQ48191947-5C4ABB2D-1EF5-45E1-8011-E49DC4315227Q52992928-5022BF2E-9BDA-44B4-AB5A-338F5A66C304Q55026417-4AF91E07-998C-4B15-A8B9-1F5DF466617A
P2860
How I monitor residual disease in chronic myeloid leukemia.
description
2009 nî lūn-bûn
@nan
2009年の論文
@ja
2009年論文
@yue
2009年論文
@zh-hant
2009年論文
@zh-hk
2009年論文
@zh-mo
2009年論文
@zh-tw
2009年论文
@wuu
2009年论文
@zh
2009年论文
@zh-cn
name
How I monitor residual disease in chronic myeloid leukemia.
@en
type
label
How I monitor residual disease in chronic myeloid leukemia.
@en
prefLabel
How I monitor residual disease in chronic myeloid leukemia.
@en
P2860
P1433
P1476
How I monitor residual disease in chronic myeloid leukemia.
@en
P2093
Jerald P Radich
P2860
P304
P356
10.1182/BLOOD-2009-02-163485
P407
P577
2009-08-06T00:00:00Z